USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer

This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), obj...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Zhejiang University. B. Science 2023-02, Vol.24 (2), p.143-156
Main Authors: Yang, Dexin, Feng, Yuqin, Lu, Haohua, Chen, Kelie, Xu, Jinming, Li, Peiwei, Wang, Tianru, Xia, Dajing, Wu, Yihua
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Effectiveness
Epidermal growth factor receptors
ErbB Receptors - genetics
Extracellular Matrix Proteins - genetics
Genomics
Growth factors
Humans
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - therapeutic use
Immunotherapy
Inhibitors
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Missense mutation
Mutation
p53 Protein
Protein Kinase Inhibitors - therapeutic use
Proto-Oncogene Proteins p21(ras) - genetics
Research Article
Sarcoma
Survival
Treatment Outcome
Tumors
USH2A protein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to identify subtypes of genomic variants associated with the efficacy of immune checkpoint inhibitors (ICIs) by conducting systematic literature search in electronic databases up to May 31, 2021. The main outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and durable clinical benefit (DCB) were correlated with tumor genomic features. A total of 1546 lung cancer patients with available genomic variation data were included from 14 studies. The Kirsten rat sarcoma viral oncogene homolog G12C ( KRAS G12C ) mutation combined with tumor protein P53 ( TP53 ) mutation revealed the promising efficacy of ICI therapy in these patients. Furthermore, patients with epidermal growth factor receptor ( EGFR ) classical activating mutations (including EGFR L858R and EGFR Δ19 ) exhibited worse outcomes to ICIs in OS (adjusted hazard ratio (HR), 1.40; 95% confidence interval (CI), 1.01–1.95; P =0.0411) and PFS (adjusted HR, 1.98; 95% CI, 1.49–2.63; P
ISSN:1673-1581
1862-1783
DOI:10.1631/jzus.B2200292